Skip to main content
OSE Immunotherapeutics logo

OSE Immunotherapeutics — Investor Relations & Filings

Ticker · OSE ISIN · FR0012127173 LEI · 969500HIUWVGY6NZSM05 PA Manufacturing
Open in API
Filings indexed 815 across all filing types
Latest filing 2026-03-23 Regulatory Filings
Country FR France
Listing PA OSE

About OSE Immunotherapeutics

https://www.ose-immuno.com/en/home/

OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering first-in-class therapies that control the immune system. The company's pipeline is concentrated in two key areas: immuno-oncology (IO) and immuno-inflammation (I&I). In immuno-oncology, its research aims to help the immune system recognize and target tumors. In immuno-inflammation, it develops treatments for autoimmune diseases and chronic inflammation by regulating immune responses. OSE Immunotherapeutics utilizes proprietary drug discovery platforms to generate novel product candidates, including monoclonal antibodies and RNA therapeutics, and collaborates with pharmaceutical partners to advance its assets through clinical development.

Recent filings

Filing Released Lang Actions
OSE Immunotherapeutics to Present at Upcoming Investor Conferences
Regulatory Filings Classification · 75% confidence The document is a short press release (under 5,000 characters) announcing OSE Immunotherapeutics’ participation in upcoming investor conferences. It does not contain financial results (ER), a full investor presentation deck (IP), or any other specific report. It is not a publication announcement of a regulatory report (RPA) but rather a general corporate announcement. Therefore, it falls into the fallback category for miscellaneous regulatory announcements.
2026-03-23 English
OSE Immunotherapeutics Announces its 2026 Financial Calendar
Report Publication Announcement Classification · 100% confidence The document is a short press release (under 5,000 characters) announcing the company's upcoming financial calendar for the year 2026. It does not contain financial results or reports themselves, but rather provides a schedule of when those reports will be released. According to the 'Menu vs Meal' rule, this is a notification of future report publications, which falls under the Report Publication Announcement (RPA) category.
2026-03-16 English
OSE Immunotherapeutics annonce son calendrier financier pour 2026
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 5,000 characters) from OSE Immunotherapeutics providing a schedule of upcoming financial reporting dates and events for the year 2026. It does not contain the actual financial reports themselves, but rather serves as a notification of when those reports will be published. According to the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA).
2026-03-16 French
OSE Immunotherapeutics confirme Marc Le Bozec comme Directeur Général pour mener la prochaine phase de croissance stratégique
Board/Management Information Classification · 100% confidence The document is a press release announcing the permanent appointment of Marc Le Bozec as the CEO of OSE Immunotherapeutics, replacing his interim role. This falls directly under the category of board and management changes.
2026-03-10 French
OSE Immunotherapeutics Confirms Marc Le Bozec as Chief Executive Officer to Lead Next Phase of Strategic Growth
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of a new permanent Chief Executive Officer (Marc Le Bozec) at OSE Immunotherapeutics. This falls directly under the category of announcements regarding changes in senior management.
2026-03-10 English
Informations relatives au nombre total de droits de vote et d’actions composant le capital
Regulatory Filings Classification · 95% confidence The document is a regulatory disclosure from OSE Immunotherapeutics regarding the total number of shares and voting rights as of February 28, 2026, in compliance with Article L. 233-8 II of the French Commercial Code and Article 223-16 of the AMF General Regulation. This type of disclosure is a standard regulatory requirement for listed companies in France to inform the market of capital structure changes. Since it does not fit into specific categories like 'Share Issue' (which would detail the issuance itself) or 'Major Shareholding' (which would detail a specific investor's stake), it falls under the general regulatory filing category.
2026-03-06 French

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.